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no episode of rastenosis either within the stent or at the stant edges. IVUS results (Table) 
show no difference when SE stent edges were compared to placebo stent edges. To the 
contrary, there was a tendency for reference lumen areas to be larger and plaque areas 
to be smaller in SE stants, especially at the distal edge. 
SE etent Bare etlmt A p-value 
N=48 N=47 
Proximal edge 
Artedal area, mm 2 14.76+5.05 13.89-1"3.69 0.87 0.37 
Lumen area, mm 2 7.65-J:3.37 6.84+~.61 0.81 0.22 
Plaque area, mm 2 7.11:~2..90 7.05:P.2.52 -0.06 0.91 
Distal edge 
Arfedal area, mm 2 11.59~:4.08 11.46+3.70 0.13 0.88 
Lumen area, mm 2 6.68+~.30 5.69~1.91 0.99 0.03 
Plaque area, mm 2 4.90+_2.53 5.77:P.2.97 0.86 0.16 
Basel~e MSA (sqrnm) Bmllne MSA (Nmm) 
Conclusions: Volumetric IVUS analysis shows that there is no "edge effect' when siroli- 
mus-eluting stants are used to treat de novo, native coronary lesions. 
9:00 a.m. 
880-3 Optimal Endpoint for  Drug-Eluting Stent: Pradletlve 
Value of Min imum Stent Area for Long-Term Stent 
Patency 
Yasohiro Honda, Eberhard Grube, Toru Kataoka, Karl E. Hauptmann, Yoohihiro Modnc, 
Seung-Ho Hur, Paul G. Yock, Peter J. Fitzgerald, SCORE investigators group, Stanford 
University, Stanford, California, Heart Center Siogburg, Siegburg, Germany, 
Minimum stant area (MSA) has been shown to be a consistent predictor of instant rest- 
enosis. However, its predictive value is limited because of biologic variability in the rest- 
enosis process. Drug-eluting stents (DES) provide a biological effect as well as a 
mechanical solution to obstructive lesions. The aim of this study was to investigate the 
relationship between post-procedure MSA and long-term stent patancy following the 
QUANAM QP2-eluting stent (DES) implantation as compared to bare metal stents 
(BMS). 
Methods: SCORE is a randomized trial comparing DES vs. BMS. To date, serial IVUS 
(baseline and 6-months) studies are available in 64 (DES 30: BMS 34) of 118 enrolled 
patients. MSA at post-procedure and minimum lumen area (MLA) at follow-up were 
obtained. 
Results: The baseline charactadstics were similar in DES and BMS. In BMS, only a 
weak correlation was observed between post-procedure MSA and follow-up MLA 
(r--0.37, p--0.03), potentially reflecting high variability in biological activity of individual 
lesion/patients. DES, however, showed a significant positive relationship with a high cor- 
relation coefficient between the two parameters (r=0.73, p<0.0001). 
Conclusions: Preliminary IVUS results suggest that past-procedure MSA may predict 
long-term stent patancy more accurately in DES than in BMS. This finding indicates that 
post-procedure MSA, a simple mechanical index, can be used as the optimal procedural 
endpoint for DES, regardless of variable degrees of biological activity in each lesion. 
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880-4 Total Supprmmlon of  Neolntimal Prol i feration After 
Implantation of Slrol lmus-Elut lng Stents: Volumetric 
Intravascular Ultrasound Results From the Randomized 
RAVEL Trial 
Alexandre Abizaid, Patdck Serruys, J. Eduardo Souse, Pim de Feyter, Andrea Abizald, 
Antonio Colombo, Giuiio Guagliumi, William Wijns, Egon Wuelfert, Made C. Morice, 
Institute Dante Pazzansse of Cardiology, Sao Pau/o, Brazil. 
Background: We previously showed, in a non-rendomized study, that Sirolimus-Eluting 
(SE) stents inhibit noeintimal proliferation. These preliminary results were tested in 
RAVEL, a double-blinded, randomized, placedo-controlled multicentar trial that com- 
pared SE BX Velocity stents (n=120) vs bare BX Velocity stenta (BS, n=118). Methods: 
The intravascular ultrasound (IVUS) sub-study included 95 pts (SE=48 and BS=47). 
Results: 
6-Month IVUS FU Sirolimus-eluting Bare stant P values 
Stant volume (mm3) 130.6-3:33.9 132:1:1 +35.6 0.842 
Lumen volume (ram3) 128.9~33.9 94.9.~40.9 < 0.0001 
Intimal hyperplasia volume (ram 3) 1.97+4.87 37.2¢27.8 < 0.0001 
Intimal hyperplesla (% of stant volume) 1.45:1:2.83 28.8+19.7 < 0.0001 
The cumulative frequency distribution curve of percent obstruction shows that 90% of the 
SE group had less than 2% of the stent occupied by neointima (left curve, Figure). Con- 
cluslons: In the RAVEL trial, IVUS analysis shows a striking inhibition of intimal hyper- 
plasia 6 months after sirolimus eluting stent implantation. 
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880-5 In t ravncu lar  Ultrasound Assessment Five Years After 
Intracoronary Gamma Radiation Therapy 
Joroe Luna-Guerra, Jos(~ A. Condado, Jorge F. Saucado, Orlando Gurdial, Isabel ifurria, 
Bogart Parra, Ron Waksman, Peter J. Fitzgerald, Paul G. Yock, Stanford University 
School of Medicine, Stanford, California, Hospital "Miguel Pdrez Carrsr~o', Caracas, 
Venezuela. 
BACKGROUND: Late effects of intracoronary gamma radiation remain unknown, as 
moot long-term studies of efficacy and potential side effects have been initiated within the 
past 3 years. We report five-year intravascular ultrasound (IVUS) findings from the initial 
cohort of patients treated with intrecoronary brechytherepy in Venezuela. 
METHOD: IVUS examinations were performed in 14 patients (15 lesions) 5 years after 
they were treated with non-centered 1921r in doses of 19-55 Gy after PTCA. IVUS inter- 
rogations were performed by manual pullback using a dynamic aperture catheter system 
(in-Vision, EndoSonioo Corp., Rancho Cordova, CA) and were analyzed off-line using 
quantitative methods (QCU) by a commercially available software package (Quent32, 
Sanders Data Systems, Palo Alto, CA). 
RESULTS: At5 years, the mean minimum lumen area (MLA) atthe treated segment was 
3.6¢1.9 ram2 (range, 0 to 8 ram), and the mean % area stenosis (%AS) at the irradiated 
segment was 50.5:P.22.9 (range, 19.4 to 100 %). IVUS defined (%AS >70%) restenosis 
was present in 4 arteries (26.7%), two of which occurred at edges. Positive remodeling 
was obsewed in 9 artedes (60%), and three true coronary aneurysms were observed (2 
focal, 1 fusiform) without evidence of thrombus, increased echo intensity of adventitia, 
presumably due to fibrosis, of moderate or greater degree occurred in 11 artades 
(73.3%). Calcification was observed in 9 arfedes (60%), mostly as >90 degree arcs and 
of deep or mixed location. 
CONCLUSIONS: In this five-year IVUS cohort, gamma radiation was associated with 
modest plaque/neointima ccumulation. Positive remodeling was common and there 
were three aneurysms (previously detected by anglo). The most striking new finding was 
fibrosis of the adventitia nd extensive deep and mixed calcification in the majodty of the 
treated segments. 
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880-6 Perl-Stent Remodel ing and Neolntlmal Response 
Fol lowing Intracoronary Radiation Therapy: A 
Volumetric Intravascular Ultrasound Study 
Hirovuki Okure. Yasuhiro Honda, David P. Lee, Shinjou Sonoda, Mamoo Nakamura, 
Grzegorz L. Kaluza, Nadir M. All, Paul G. Yock, Albert E. Raizner, Peter J. Fitzgerald, 
Stanford University, Stanford, California, Baylor College of Medicine, Houston, Texas. 
A recent volumetric IVUS study has suggested the role of peri-stent remodeling in subse- 
quent neointimal response. The aim of this study was to investigate the potential relation- 
ship between peri-stent remodeling and neointimal proliferation following intracoronary 
brechytherepy with a beta source wire (32p). 
Methods: Sedal (baseline and follow-up) volumetric IVUS analyses were performed in 
23 stentad lesions treated with intrecoronary beta radiation enrolled in the PREVENT 
study. Vessel (W), stent (SV) and lumen volumes (LV) were obtained using Simpaon's 
method. The volumes of plaque and neointima outside the stent (ped-stant volume, PSV) 
and neointima within the stent (intrastent volume, ISV) were computed. Peri-stant remod- 
eling was defined present if AVV > 0 (Group P) and absent if AVV_<0 (Group N). 
Results: At baseline, W, LV, SV, PSV and ISV were similar between Group P (n=12) 
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and Group N (n=11). However, AISV was significantly less in Group P than in Group N 
(4.9~:5.2 vs. 13.8+12.3 mm 3, p=0.03). Less ~VV tended to be associated with greater 
AISV although this correlation did not reach statistical significance (r=0.26, p=0.22). 
Conclusions: The IVUS substudy of PREVENT demonstrated a variable degree of ves- 
sel remodeling exterior to the coronary stent during the follow-up period. In addition to 
the direct anti-proliferetive effect of brachytherapy, the positive pad-stent remodeling may 
be another contributing factor to intrastent neointimal suppression following beta irradia- 
tion. 
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887-2 Inter-Aeaay Variability in the Degree of Platelet 
Inhibition Following GPIIb/Illa Receptor Blockade in 
Patients Undergoing Coronary Intsrventlon: A 
Comparison of Three Different Point-of-Care Assays 
Daniel Softer. William W. O'Neill, Kishore J. Harlai, Simon R. Dixon, Judith Bouts, Robert 
D. Safian, Cindy L. Grines, lasam Mouasa, Gary S. Roubin, Jeffrey W. Moses, William 
Beaumont Hospital, Royal Oak, Michigan, Lenox Hill Heart and Vascular Institute, New 
York, New York. 
Background: The degree of platelet inhibition (PI) induced by GPIth/llla antagonists has 
been shown to influence clinical outcomes following percutaneous coronary intervention 
(PCI). There is no comparative data on the degree of PI using different commercially 
available point-of-care PI assays. 
Methods: We prospectively enrolled 24 pts (66 ± 10 yrs, 18 males) who received a 
GPifb/llla inhibitor during PCI. Pts received tirofiban; n=15 (10mcg/kg, 0.15mcg/kg/min), 
eptifibitide; n=7 (single bolus; 180mcg/kg, 2mcg/kg/min), and abciximab; n=2 (0.25mg/ 
kg, 0.125mcg/kg/min). We compared the degree of PI using 3 different assays: 1) 
20p.mol ADP/citrate in the IchorTM piatelet analyzer (Helena Laboratories, Beaumont, 
TX), 2) iso-TRAP/citrate and 3) iso-TRAP/PPACK as piatelet agonists/enticoaguiants 
respectively in the UltagraTM system (Accumetrics, San-Diego, CA). PI was measured in 
all pts 30 min following GPIIb/llia bolus, with each assay performed on the same blood 
sample. 
Results: The mean ± SD values of PI following GPIIb/Itia administration are shown 
below. 
Conclusion: There is significant variation in the degree of PI assessed by the three 
assays. The greater inter-patient variability and the lower mean PI, detected by the 
IchorTM system may enhance patient stratification based upon response to GPIIb/llla 
inhibitors. The practical implications of these findings need to be validated in large-scale 
clinical outcome trials. 
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887-1 Elevated Troponin Following Percutaneous Coronary 
Intervention Predicts Subsequent Events: Results From 
the ESPRIT Trial 
Christoeher K. Dyke. Danny K. Benjamin, Jr., Charlotte L. Nelson, Kdstin Newby, Conor 
O'shea, Warren Cantor, Can Nguyen, John H. Alexander, Michael M. Kitt, James E. 
Tcheng, Duke Clinical Research Institute, Durham, North Carolina. 
Background: Few data exist to assess the significance of troponin following stent percu- 
tanecus coronary intervention (PCI). We examined the predictive utility of post-PCI tropo- 
nin for subsequent cardiac events in the ESPRIT trial. Methods: Troponin was measured 
in local laboratories at the discretion of the site investigator. Of participants that had a 
post-PCI troponin (n=392), 52 were excluded due to an endpoint of death or MI (core CK- 
MB 3X upper limit of normal (ULN)) at 48 hours. In the remaining population (n--341), we 
assessed the relation of troponin elevation to occurrence of the ESPRIT-defined compos- 
ite of death, MI, and TVR to 365 days in a Cox proportional-hazards (PH) model. We 
dichotomized (<=ULN or >ULN) troponin and included it as a time-dependent covadate. 
Results: The baseline characteristics were similar in the overall tdal population (n=2064), 
participants with post-procedure troponin measured (n=341), and participants with an 
elevated (n=123) or normal (n=218) tmponin. An elevated post-PCI troponin was associ- 
ated with a 3-fold higher risk for subsequent cardiac events (HR-.-.-~.97;p=0.019). These 
results did not differ significantly with troponin >3X ULN in the time to event model. Con- 
clusion: In a low-risk patient population undergoing elective PCI, an elevated post-PCI 
troponin >ULN was associated with a significant increase in subsequent cardiac events. 
Development of strategies to prevent even minor myocardial necrosis as detected by 
troponin post-PCI is warranted. 
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887-3 Point-of-Care Measurement of Platelet Function Before 
Angioplasty Strongly Predicts Future Target Veuel 
Reveacularization 
Steven R. Steinhubl. Jorge F. Saucedo, David C. Sane, Peter B. Berger, David J. 
Molitemo, James E. Tcheng, Dean J. Kereiakes, Wilford Hall Medical Center, San 
Antonio, Texas, Lindner Research Center, Cincinnati, Ohio. 
Background: Baseline plateiat activation correlates with the need for target vessel revascularo 
ization (TVR) following PCI but is of limited clinical ~lity due to the need for specialized test- 
ing. The Ultegra-RPFA is a simple, point-of-care assay approved for use in monitoring 
plateiet function in patients treated with GPIIb/llia antagonists that also quantifies the 
patient's baseline platelet function. 
Method: As part of the GOLD study, baseline Platslet Activation Units (PAU) were measured 
using the Uitegra-RPFA in 500 patients undergoing a pemutanecus coronary intervention 
with the adjunctive use of a GPIII:YlIla antagonist. TVR at 7 months was evaluated in a subset 
of 194 abciximab-treatad patients and analyzed with respect to baseline platelet function. 
Results: Baseline plateiet function ranged from 52 to 471 PAU (median 234). Patients with 
the lowest PAU values at baseline, consistent with more activated or "exhausted" platelets 
had a significantly greater risk of TVR than those paitents with highest baseline PAU levels 
(Figure). 
Conclusion: These results confirm that increased levels of plateiet a~vation prior to PCI are 
assooated with an increased risk of TVR, and confirm that this can now be easily determined 
utilizing a simple point.of-care assay. Routine platelet function monitoring may help to opti° 
mize the future use of more expensive therapies designed to prevent restenosis. 
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